GlassScriptPhysician profile
Adam J Rubinstein
NPI 1033174388
$50,272.84
in general payments reported to CMS, 2019-2025
23 companies · $939 in 2025
The $939 reported for 2025 was more than what a typical Plastic Surgery provider received nationally (typical 2025 total: $380).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $28K · 2020: $17K · 2021: $425 · 2022: $1,748 · 2023: $1,049 · 2024: $718 · 2025: $939.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,707.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,706.83 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Apyx Medical Corporation | $41,742.96 | 2019-2020 | |
| Allergan, INC. | $3,515.26 | 2019-2022 | |
| Sientra, INC. | $1,103.16 | 2019-2022 | |
| Polynovo North America LLC | $615.59 | 2023-2025 | Novosorb Btm |
| Galderma Laboratories, L.P. | $577.07 | 2020-2025 | Dysport |
| Merz North America, INC. | $549.61 | 2019-2024 | |
| Solta Medical, A Division of Bausch Health US, LLC | $308.17 | 2019-2025 | Clear+Brilliant |
| Motiva USA, LLC | $298.05 | 2024-2025 | |
| Revance Therapeutics, INC. | $244.87 | 2024-2025 | Daxxify |
| Abbvie INC. | $226.80 | 2023-2025 | Botox |
| Surgical Innovation Associates, INC. | $200.83 | 2022 | |
| Innovation Technologies INC | $198.00 | 2023 | Irrisept |
| Stryker Corporation | $172.86 | 2023 | Spy-Phi System |
| Axogen | $124.99 | 2023 | Avance Nerve Graft |
| Kerecis Limited | $96.29 | 2023 | Kerecis Omega3 Surgiclose, Kerecis Omega3 Graftguide, Kerecis Omega3 Marigen |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Musculoskeletal Transplant Foundation INC. | $94.06 | 2024 | |
| Lilly USA, LLC | $54.79 | 2025 | Zepbound, Mounjaro |
| Davol INC. | $35.96 | 2022 | |
| Glaxosmithkline, LLC. | $33.28 | 2019-2023 | Arexvy, Shingrix |
| Bard Peripheral Vascular, INC. | $29.09 | 2021 | |
| Regeneron Healthcare Solutions, INC. | $21.59 | 2024 | Eylea Hd, Eylea |
| Guard Medical INC. | $16.59 | 2024 | Npseal Large |
| Mentor Worldwide LLC | $12.97 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Adam Rubinstein listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.